Dexcom (NSDQ:DXCM) this week was ordered to pay attorney’s fees in a spat with rival AgaMatrix over patents related to continuous glucose monitoring technology.
The ruling came alongside a final judgement of non-infringement in favor of AgaMatrix from Judge S. James Otero of the US District Court for the Central District of California Western Division, according to court documents.
Read the whole story on our sister site, Drug Delivery Business